Beijing Advaccine Raises $4.3 Million for Coronavirus Vaccine Development

01:37 EST 12 Feb 2020 | ChinaBio Today

Beijing Advaccine Biotechnology raised $4.3 million in a new funding that will be used to test a coronavirus (2019-nCoV) vaccine. Two weeks ago, Advaccine and Inovio of the US announced a partnership to develop a coronavirus vaccine, with Inovio receiving a $9 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to underwrite the work. Advaccine will be in charge of Phase I China testing that will parallel Inovio's. Advaccine expects to complete China preclinical development of the vaccine in 4 to 6 months and then apply for clinical testing approval. More details....

Share this with colleagues:

Original Article: Beijing Advaccine Raises $4.3 Million for Coronavirus Vaccine Development


More From BioPortfolio on "Beijing Advaccine Raises $4.3 Million for Coronavirus Vaccine Development"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...